PharmaBlock has successfully overcome the challenges associated with the application of sec-butyllithium by leveraging continuous flow technology. Following multiple rounds of wet testing, the project achieved continuous and stable operation for more than ten days and successfully completed production and delivery at the hundred-kilogram scale.

Results from prespecified assessment of End of Progression in the RAPIDe-3 Phase 3 study and clinical relevance of this newly-defined endpoint detailed in an oral presentation Evidence on the cardiovascular safety profile of deucrictibant in clinical studies to date presented

"Drive For Change," authored by leaders from Volv Global, Sanofi, Fondation Ipsen, Unitechpharma, and brave2change, sets out a strategic roadmap to overcome the systemic barriers holding back rare disease drug development. Approximately 95% of identified rare diseases have no approved treatment, with an economic burden estimated at nearly $1 trillion annually in the United States alone; Drive For

Xlife Sciences AG (SIX: XLS, «Xlife Sciences») a Swiss incubator and accelerator of life sciences companies, today announces that its portfolio company VERAXA Biotech AG («VERAXA») has successfully completed its previously announced business combination with Voyager Acquisition Corp. and will commence trading on the NASDAQ Capital Market under the ticker symbols «VRXA» and «VRXAW» on June

First-in-human study of  SOT106 to be initiated in second half of 2026, advancing a differentiated LRRC15 ADC toward early clinical signal SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to SOT106 for the treatment of osteosarcoma, reinforcing its potential as a